Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.76

-1.4001 (-8.16%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

12:29
11/30/16
11/30
12:29
11/30/16
12:29

Paulson opposed Valeant sale of Salix, deal now 'all but dead,' CNBC says

Valeant's (VRX) potential deal to sell its Salix business to Japan's Takeda Pharma (TKPYY) is "all but dead," reports CNBC's Scott Wapner, citing sources. Price disagreements emerged at the eleventh hour, as Takeda wanted to cut the deal's royalty payments in half, sources told Wapner, adding that Valeant "didn't really want to sell in the first place." Wapner's sources also told him that John Paulson, one of the largest investors in Valeant, was against the deal, saying it would cut future growth prospects.

VRX

Valeant

$15.76

-1.4001 (-8.16%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

VRX Valeant
$15.76

-1.4001 (-8.16%)

11/18/16
DBAB
11/18/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche still likes near-term setup for Valeant shares
Deutsche Bank analyst Gregg Gilbert said yesterday that he still likes the near-term setup for shares of Valeant Pharmaceuticals after federal prosecutors announced criminal charges against former executive Gary Tanner and the former CEO of Philidor. It is "good to see" that Valeant and other senior executives were not charged, Gilbert told investors in a research note. The charges could be an important step forward as the company and new management team distance themselves from the past, Gilbert wrote. The analyst points out that the bar for 2016 has already been lowered and that new CFO Paul Herendeen thinks of guidance as a commitment. Gilbert keeps a Hold rating on Valeant with a $24 price target. The stock closed yesterday up 12c to $17.98.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
TKPYY Takeda Pharmaceutical Co. Ltd.
$20.97

-0.035 (-0.17%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

IBM

IBM

$180.67

-0.76 (-0.42%)

17:18
02/20/17
02/20
17:18
02/20/17
17:18
Hot Stocks
IBM expands Watson Health Cloud capabilities, introduces health consulting unit »

At the 2017 Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

TUWOY

Tullow Oil

$1.59

-0.03 (-1.85%)

17:18
02/20/17
02/20
17:18
02/20/17
17:18
Upgrade
Tullow Oil rating change  »

Tullow Oil upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFLYY

Air France-KLM

$6.83

0.29 (4.43%)

17:17
02/20/17
02/20
17:17
02/20/17
17:17
Upgrade
Air France-KLM rating change  »

Air France-KLM upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EUTLF

Eutelsat Communications

17:16
02/20/17
02/20
17:16
02/20/17
17:16
Upgrade
Eutelsat Communications rating change  »

Eutelsat upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSFT

BroadSoft

$43.90

0.6 (1.39%)

17:07
02/20/17
02/20
17:07
02/20/17
17:07
Hot Stocks
BroadSoft says contact center platform selected by American Red Cross »

BroadSoft announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 28

    Feb

FET

Forum Energy

$20.10

-0.75 (-3.60%)

16:53
02/20/17
02/20
16:53
02/20/17
16:53
Hot Stocks
Forum Energy says CEO Gaut to become executive chairman, appoints Iyyanki as CEO »

Forum Energy Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$57.61

-1.42 (-2.41%)

, OISHY

Oil Search

16:48
02/20/17
02/20
16:48
02/20/17
16:48
Hot Stocks
Jacobs gets letter of intent from Oil Search for services in New Guinea »

Jacobs Engineering Group…

JEC

Jacobs Engineering

$57.61

-1.42 (-2.41%)

OISHY

Oil Search

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USNA

USANA

$58.15

-1.1 (-1.86%)

16:42
02/20/17
02/20
16:42
02/20/17
16:42
Hot Stocks
USANA says subsidiary becomes official sponsor of China sports training bureau »

USANA Health Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICLR

ICON plc

$85.68

-2.1 (-2.39%)

16:37
02/20/17
02/20
16:37
02/20/17
16:37
Hot Stocks
ICON selected by FDA to validate outcome instruments for antibacterial trials »

ICON plc announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALV

Autoliv

$105.87

-1.46 (-1.36%)

16:33
02/20/17
02/20
16:33
02/20/17
16:33
Hot Stocks
Autoliv raises quarterly dividend to 60c per share »

Autoliv announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

HCM

Hutchison China MediTech

$13.38

-0.02 (-0.15%)

16:32
02/20/17
02/20
16:32
02/20/17
16:32
Hot Stocks
Hutchison China MediTech initiates Phase 2 study of savolitinib in lung cancer »

Hutchison China MediTech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

, PLKI

Popeyes

$66.12

-0.26 (-0.39%)

15:46
02/20/17
02/20
15:46
02/20/17
15:46
Periodicals
Restaurant Brands in advanced talks to buy Popeyes, Bloomberg says »

Restaurant Brands (QSR)…

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

PLKI

Popeyes

$66.12

-0.26 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

ACN

Accenture

$121.23

0.51 (0.42%)

15:17
02/20/17
02/20
15:17
02/20/17
15:17
Hot Stocks
Accenture announces intent to acquire SinnerSchrader »

Accenture announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGG

CGG SA

15:13
02/20/17
02/20
15:13
02/20/17
15:13
Hot Stocks
CGG SA says secures consent from debt holders »

CGG SA CGG announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PI

Impinj

$31.17

-4.19 (-11.85%)

15:05
02/20/17
02/20
15:05
02/20/17
15:05
Hot Stocks
Impinj announces partnership, platform integration with STANLEY Healthcare »

Impinj announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

HRS

Harris

$109.46

0.81 (0.75%)

15:03
02/20/17
02/20
15:03
02/20/17
15:03
Hot Stocks
Harris wins $189M contract with UAE military »

Harris has received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$100.52

-0.3 (-0.30%)

15:01
02/20/17
02/20
15:01
02/20/17
15:01
Hot Stocks
Alibaba announces strategic partnership with Bailian Group »

Alibaba and Chinese…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 19

    Mar

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

, VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

14:58
02/20/17
02/20
14:58
02/20/17
14:58
Hot Stocks
Sierra Wireless says connected car products selected by Volkswagen »

Sierra Wireless (SWIR)…

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$10.62

0.08 (0.76%)

, CLMS

Calamos

$8.24

-0.03 (-0.36%)

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Progenics to replace Calamos in S&P 600 as of 2/20 close »

Calamos Asset Management…

PGNX

Progenics

$10.62

0.08 (0.76%)

CLMS

Calamos

$8.24

-0.03 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 01

    Mar

SFLY

Shutterfly

$48.06

0.66 (1.39%)

, VASC

Vascular Solutions

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Shutterfly to replace Vascular Solutions in S&P 600 as of 2/20 close »

S&P MidCap 400…

SFLY

Shutterfly

$48.06

0.66 (1.39%)

VASC

Vascular Solutions

TFX

Teleflex

$179.91

1.86 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NKTR

Nektar

$13.10

0.12 (0.92%)

, BMY

Bristol-Myers

$54.59

0.31 (0.57%)

14:48
02/20/17
02/20
14:48
02/20/17
14:48
Hot Stocks
Nektar reports Phase 1 data on NKTR-214 in kidney cancer »

Nektar Therapeutics…

NKTR

Nektar

$13.10

0.12 (0.92%)

BMY

Bristol-Myers

$54.59

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

XNCR

Xencor

$24.28

0.5 (2.10%)

14:38
02/20/17
02/20
14:38
02/20/17
14:38
Hot Stocks
Xencor announces data presentation on XmAb5871 »

Xencor announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

RHHBY

Roche

$30.53

0.02 (0.07%)

14:35
02/20/17
02/20
14:35
02/20/17
14:35
Hot Stocks
Genentech reports Phase 2 data on Tecentriq combo in kidney cancer »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 09

    Mar

  • 26

    Jun

RVSB

Riverview Bancorp

$7.50

-0.11 (-1.45%)

14:30
02/20/17
02/20
14:30
02/20/17
14:30
Hot Stocks
Breaking Hot Stocks news story on Riverview Bancorp »

Riverview Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCN

Ocwen

$5.24

0.09 (1.75%)

14:27
02/20/17
02/20
14:27
02/20/17
14:27
Hot Stocks
Ocwen reaches settlement, termination of California consent order »

Ocwen Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.